Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

NIH Director's New Innovator Award (DP2 Clinical Trial Optional)

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

N/A

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedSep 3

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUSA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health

View Agency Profile

Office AddressUSA

Contacts

NIH Director's New Innovator Award Program

contact@example.gov

Full Description

Show more

The NIH Director's New Innovator Award supports exceptionally creative early-stage investigators pursuing bold, innovative research with the potential to transform important areas of science relevant to the NIH mission. Applications are welcome across all fields relevant to NIH. The award complements other NIH programs that support early-stage investigators and is part of the NIH Common Fund's High-Risk, High-Reward Research Program.

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NIH Director's Pioneer Award (DP1 Clinical Trial Optional)

POSTED

DEADLINE

NIH Director's Early Independence Award (DP5 Clinical Trial Optional)

POSTED

DEADLINE

NIH Director's Transformative Research Award (R01 Clinical Trial Optional)

POSTED

DEADLINE

Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)The National Institute on Minority Health and Health Disparities within the National Institutes of Health is issuing a forecast for planning grants titled Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes. These grants are designed to support preparatory, feasibility, and pilot activities that advance intervention development or solutions-oriented etiologic studies. A mandatory requirement for all projects is that they must be co-developed with community partners to ensure the effectiveness of the health outcomes being addressed. Priority areas for funding include formative studies on understudied contributors to chronic diseases like cancer and diabetes, as well as the adaptation and pilot-testing of interventions for maternal and infant health. Additionally, the program seeks feasibility and acceptability testing for strategies aimed at reducing behavioral risk factors, such as poor nutrition and smoking, to promote sustained behavior change and measurable improvements in health for NHPI populations.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources (S15 Clinical Trial Not Allowed)The National Institutes of Health, under the Department of Health and Human Services, has issued a forecast for the Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources program. This funding opportunity is designed for eligible shared biomedical research facilities, such as core facilities, biorepositories, and model resource facilities, to acquire new small instruments or scientific equipment. The primary objective is to enhance the operational efficiency and capabilities of resources shared by multiple researchers. Priority is given to requests for small instruments utilizing emerging technologies or those that generate physical, chemical, or biomaterial outputs rather than standard digital data. It is important to note that funding is restricted and cannot be used for building-level infrastructure or highly specialized instruments that only indirectly support research. Clinical trials are not allowed under this specific opportunity.

Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

DEADLINE

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2The National Institutes of Health, through the National Institute on Drug Abuse, is forecasting Phase 2 of the Single Cell Opioid Responses in the Context of HIV (SCORCH) program. This initiative builds upon Phase 1 research by utilizing single-nucleus datasets from human and animal postmortem brain tissue to investigate the interactions between Substance Use Disorder and HIV disease progression within the Central Nervous System. The program aims to employ advanced single cell approaches, including the study of RNA splicing, epigenomic features, and spatial interactions, to conduct both data mining and hypothesis-driven research. The ultimate goal is to enhance the mechanistic understanding of how these conditions affect the brain at subcellular and circuit levels to identify potential targets for novel therapeutic interventions.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Translational Research in Maternal and Pediatric Pharmacology and TherapeuticsThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to issue a Notice of Funding Opportunity for translational research in maternal and pediatric pharmacology and therapeutics. This initiative aims to improve safe and effective precision therapeutics for pregnant women, lactating women, infants, children, and adolescents. The program focuses on advancing precision medicine via novel tools and technologies, developing safer therapeutics, improving patient-provider communication regarding drug safety, and scaling evidence-based interventions. This forecast is part of the agency's stewardship of the Best Pharmaceuticals for Children Act and recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. While the project outlines clear goals for enhancing medication effectiveness and safety across these specific patient populations, applications are not currently being solicited. Interested parties can coordinate with the Obstetric and Pediatric Pharmacology and Therapeutics Branch for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)The Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) is a legislatively mandated Centers of Excellence program managed by the National Institutes of Health under the Department of Health and Human Services. This initiative focuses on expanding and intensifying basic, translational, and clinical research regarding muscular dystrophy through interdisciplinary collaboration and shared resources. By supporting innovative center-based projects and providing robust training environments for emerging scientists, the program aims to achieve research outcomes that exceed the capabilities of stand-alone grants. A critical component of the program is its commitment to patient-centered research, actively engaging patient and advocacy communities to increase awareness and ensure that study designs are informed by patient perspectives. This forecast opportunity is supported by several grant authorities, including 42 U.S.C. 281, 283g, 285g, and 284h. Interested parties can coordinate with the NICHD Intellectual and Developmental Disabilities Branch for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is seeking a coordinated, milestone-driven research project titled Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes. This initiative aims to integrate large, longitudinal, and multimodal datasets from various T1D research consortia to examine how different biological processes, tissues, and organs interact to drive the development and progression of the disease. By combining human pancreas and clinical data, the project seeks to uncover new insights into T1D biology, identify biomarkers, and inform personalized approaches for prevention and treatment. To achieve these goals, the project will focus on the development and testing of advanced multimodal AI models and AI-enabled research workflows. Key technical objectives include creating new methods for data integration and generating privacy-preserving synthetic datasets. This effort is designed to move beyond the limitations of individual studies to provide a comprehensive understanding of the different forms and stages of Type 1 Diabetes, ultimately accelerating the advancement of precision medicine.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Established Clinician Investigator Award to Support Mentoring (KS1)The Established Clinician Investigator Award to Support Mentoring (KS1) is a forecast opportunity issued by the National Institutes of Health under the Department of Health and Human Services. This award is designed to provide established clinician investigators with a sustained period of protected time, enabling them to deliver high-quality mentoring and guidance to early-career clinician research scientists. The program is managed by the Division of Biomedical Research Workforce, which serves as the primary point of contact for interested parties. While specific performance locations and set-aside details are not listed, the award aims to strengthen the pipeline of clinician researchers through structured mentorship support.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Infrastructure – Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC)The National Institutes of Health, through the National Institute of Neurological Disorders and Stroke and the National Heart, Lung and Blood Institute, is seeking to provide continued support for the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). This initiative focuses on conducting clinical trials to improve outcomes for patients experiencing non-stroke neurological and cardiovascular emergencies within pre-hospital or emergency department settings by identifying effective early-stage treatments. The program specifically seeks to establish a Clinical Coordinating Center (CCC) and a Data Coordinating Center (DCC) to support the network's infrastructure. While this notice serves as a forecast to allow potential applicants time to form collaborations and prepare responsive applications, formal solicitations are not currently being accepted.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Mentored Career Transition Award (KT1/R00)The Mentored Career Transition Award (KT1/R00), issued by the National Institutes of Health under the Department of Health and Human Services, is a biphasic grant designed to transition postdoctoral researchers into independent, tenure-track faculty roles. The award provides up to five years of total support, beginning with a mentored career development phase lasting one to two years. The second phase offers up to three years of independent research funding, which is contingent upon the recipient's satisfactory progress during the initial phase and the procurement of an approved, research-intensive faculty position. This forecasted opportunity is managed by the Division of Biomedical Research Workforce.

Professional and Management Development Training

POSTED

DEADLINE